Literature DB >> 17376791

No change in calculated creatinine clearance after tenofovir initiation among Thai patients.

Angele Gayet-Ageron1, Jintanat Ananworanich, Thidarat Jupimai, Ploenchan Chetchotisakd, Wisit Prasithsirikul, Sasiwimol Ubolyam, Michelle Le Braz, Kiat Ruxrungtham, James F Rooney, Bernard Hirschel.   

Abstract

OBJECTIVES: Thai patients have a lower average body weight than patients from western Europe or the USA. Tenofovir is largely prescribed at the standard dosage of 300 mg once daily: therefore, the per kilogram dose is higher in Thailand than in the USA. We asked the question whether this higher per kilogram dose was associated with more nephrotoxicity.
METHODS: Thai patients from the Staccato trial were treated with tenofovir/lamivudine combined with ritonavir-boosted saquinavir. Creatinine values were measured before the start of tenofovir and then every 12 weeks. Renal function was assessed using the Cockcroft-Gault formula and the MDRD formula. To compare CL(CR) before and after tenofovir, the t-paired or Wilcoxon signed rank tests were used. One-way analysis of variance and Spearman's correlation coefficient were used to study CL(CR) longitudinally.
RESULTS: CL(CR) remained stable after a median of 21 weeks on tenofovir (difference of +1.06 mL/min; 95% CI -2.7-4.8, P=0.58), even among patients with underlying diseases. The mean CL(CR) remained stable across time (P=0.17).
CONCLUSIONS: We did not find renal dysfunction on tenofovir among Thai patients included in the Staccato trial. Tenofovir could be safely prescribed at a standard dosage of 300 mg once daily in the Thai population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376791     DOI: 10.1093/jac/dkm064

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?

Authors:  Jérôme Tourret; Gilbert Deray; Corinne Isnard-Bagnis
Journal:  J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 10.121

2.  Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.

Authors:  Takeshi Nishijima; Hirokazu Komatsu; Hiroyuki Gatanaga; Takahiro Aoki; Koji Watanabe; Ei Kinai; Haruhito Honda; Junko Tanuma; Hirohisa Yazaki; Kunihisa Tsukada; Miwako Honda; Katsuji Teruya; Yoshimi Kikuchi; Shinichi Oka
Journal:  PLoS One       Date:  2011-07-25       Impact factor: 3.240

3.  Tenofovir nephrotoxicity: 2011 update.

Authors:  Beatriz Fernandez-Fernandez; Ana Montoya-Ferrer; Ana B Sanz; Maria D Sanchez-Niño; Maria C Izquierdo; Jonay Poveda; Valeria Sainz-Prestel; Natalia Ortiz-Martin; Alejandro Parra-Rodriguez; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  AIDS Res Treat       Date:  2011-06-07

4.  Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.

Authors:  Takeshi Nishijima; Hiroyuki Gatanaga; Hirokazu Komatsu; Kunihisa Tsukada; Takuro Shimbo; Takahiro Aoki; Koji Watanabe; Ei Kinai; Haruhito Honda; Junko Tanuma; Hirohisa Yazaki; Miwako Honda; Katsuji Teruya; Yoshimi Kikuchi; Shinichi Oka
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

5.  Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.

Authors:  Sanjay N Pujari; Colette Smith; Abhimanyu Makane; Mike Youle; Margaret Johnson; Vivek Bele; Kedar Joshi; Digamber Dabhade; Sanjay Bhagani
Journal:  BMC Infect Dis       Date:  2014-03-29       Impact factor: 3.090

6.  Review of tenofovir-emtricitabine.

Authors:  Saba Woldemichael Masho; Cun-Lin Wang; Daniel E Nixon
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.